Filing step-change
TAMBOLIIN · 2026-10
Quarterly observations that moved versus the prior period in 2026-10. Facts only — not a call to act.
Narrative date 2026-10-21 · Evidence medium
Tamboliin's 85.7% gross margin accelerated to, up from 14.32%.
Raw Evidence
Source observations behind the synthesis narrative.
| Metric | Value | Trend | |
|---|---|---|---|
| GROSS_MARGIN | 85.7 % | 14.32 | ▲ |
| MARGINAL_OPERATING_LEVERAGE | 14.32 % | 12.93 | ▲ |
| REVENUE_GROWTH_YOY | 10.3 % | 64.8 | ▼ |
Cite this
Source: Samhati filing step-change for TAMBOLIIN (2026-10). Observation: Tamboliin's 85.7% gross margin accelerated to, up from 14.32%. Evidence quality: medium. Not investment advice — no buy, sell, or hold recommendation. Full narrative (Pro): https://samhati.ai/pricing Page: https://samhati.ai/stock/tamboliin/q/2026-10
Other periods